Wincal Biopharma

Wincal Biopharma is a preclinical-stage biotechnology company focused on developing first-in-class small molecule therapeutics targeting the Wnt and calcium signaling pathways. The company's research centers on addressing high-need areas in fibrosis and oncology, with a particular emphasis on idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH). By leveraging its proprietary platform to modulate complex intracellular signaling, Wincal aims to disrupt disease progression in chronic inflammatory and fibrotic conditions. The company is headquartered in the San Francisco Bay Area and is led by a team with significant experience in drug discovery and development.